IDH2 and brain neoplasm: Both methods have separately shown to be effective for glioma grading,15,16 brain tumor classification,17 and differentiation of IDH-wildtype (wt) and IDH-mutant (mut) neoplasms—a key molecular marker in the 2021 edition of WHO CNS classification system.18–20